Hydralazine treatment alters body composition in the rabbit model of obesity.
Hydralazine treatment alters body composition in the rabbit model of obesity.
复制标题
肼屈嗪治疗改变了肥胖兔模型的身体成分。
DOI：
10.1111/j.1365-201x.2004.01283.x
复制
发表时间：
2004
期刊：
影响因子：
--
通讯作者：
Cohen,JoshuaS
中科院分区：
文献类型：
--
作者：
Carroll,JoanF;King,JeffreyW;Cohen,JoshuaS
目的：在动物实验中，肼嗪常用作单药治疗，但其潜在的副作用很少被承认。据称的副作用发生于交感神经和肾素-血管紧张素系统激活，包括心动过速、水肿和恶心。我们假设这些副作用会通过增加身体水分和/或减少身体脂肪来改变身体成分。方法：将雌性新西兰大白兔分为瘦、胖对照组和肼嗪治疗组。瘦兔饲喂维持饲粮12周；肥胖的兔子吃的是AD - lib高脂肪饲料。瘦型和肥胖型Hydralazine组分别给予6和10-14 mg kg - 1day - 1。用3个2 - 3 g的全身匀浆样品测定体成分，并用2 × 2的方差分析日粮与肼嗪的影响。结果：与对照组相比，Hydralazine处理的动物体脂较低（分别为15.7±1.1和21.8±1.0%），体水较高（分别为59.8±0.8和55.4±0.6%）。虽然肥胖对照组比使用肼嗪治疗的肥胖动物更重（分别为5.12±0.09对4.73±0.11 kg），并且总体饲料消耗量更高（分别为13.5±0.4对11.8±0.4 kg），但随后使用体重或饲料消耗量没有差异的亚群进行的分析得出了相同的结论。血浆肾上腺素和去甲肾上腺素在对照组和肼组之间没有差异。结论：使用肼嗪控制血压可改变机体成分。肼嗪的直接或间接作用可能影响正在研究的生理系统。由于其内分泌功能，脂肪组织的改变可能特别值得关注。
Aims:While hydralazine is commonly used as monotherapy in animal studies, its potential side effects are seldom acknowledged. Purported side effects occur from sympathetic and renin–angiotensin system activation, and include tachycardia, oedema, and nausea. We hypothesized that these side effects would alter body composition by increasing body water and/or decreasing body fat.Methods:Female New Zealand White rabbits were divided into lean and obese control and hydralazine‐treated groups. Lean rabbits ate a maintenance diet for 12 weeks; obese rabbits ate an ad lib high fat diet. Hydralazine was administered at 6 and 10–14 mg kg−1day−1for lean and obese hydralazine groups, respectively. Body composition was determined using triplicate 2–3 g samples of whole body homogenate, and analysed using 2 × 2anovafor diet vs. hydralazine effects.Results:Hydralazine‐treated animals had lower body fat (15.7 ± 1.1 and 21.8 ± 1.0%, respectively) and higher body water (59.8 ± 0.8 and 55.4 ± 0.6%, respectively) compared with controls. While obese controls were heavier than obese hydralazine‐treated animals (5.12 ± 0.09 vs. 4.73 ± 0.11 kg, respectively) and had greater overall feed consumption (13.5 ± 0.4 vs. 11.8 ± 0.4 kg, respectively), a subsequent analysis using subsets that did not differ in body weight or feed consumption yielded the same conclusions. Plasma adrenaline and noradrenaline did not differ between control and hydralazine‐treated groups.Conclusions:Use of hydralazine to control blood pressure alters body composition. Direct or indirect effects of hydralazine may impact physiological systems under study. Alterations in adipose tissue may be of particular concern because of its endocrine function.